INSUPen is being used to deliver two Biocon insulin products: Basalog, a long-lasting formulation; and Insugen, a recombinant human form. By delivering the products using the i-pen technology from Haselmeier Biocon hopes to ensure reliable and accurate dosing while increasing convenience.
Rakesh Bamzai, president, marketing at Biocon, said: “I am confident that INSUPen will be a delight for patients and a value enhancer for all stakeholders.” The i-pen includes dose correction to avoid errors and other features designed to ease self-administration by patients.